查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496719

抗體治療市場：按形式、給藥途徑、來源、疾病領域和最終用戶分類 - 全球預測 2024-2030

Antibody Therapeutics Market by Format (Antibody Fragment, Bispecific Antibody, Monoclonal Antibody), Route of Administration (Intravenous, Subcutaneous), Source, Disease Areas, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年抗體治療市場規模為2,487.9億美元，預計2024年將達2,857.7億美元，2030年將達6,575億美元，複合年成長率為14.89%。

抗體療法是一組使用抗體來模擬或增強免疫系統對抗疾病的能力的治療方法。抗體療法的高精度使得客製化治療能夠提供比傳統藥物更高的特異性和更低的毒性，使其能夠有效治療包括癌症、自體免疫疾病和感染疾病。慢性病的增加和全球醫療保健支出的增加導致抗體療法的採用增加。然而，高昂的開發成本以及漫長而複雜的監管核准限制了抗體療法的普及。然而，醫療技術的進步提高了抗體的生產效率。此外，新一代抗體的出現以及政府對癌症治療和護理的支持舉措預計將為抗體治療市場提供潛在機會。

主要市場統計
基準年[2023] 2487.9億美元
預測年份 [2024] 2857.7億美元
預測年份 [2030] 6575億美元
複合年成長率（%） 14.89%

區域洞察

在美洲，抗體治療市場在完善的研發生態系統、廣泛的專利組合和高醫療保健支出的支持下呈現強勁成長。此外，美洲是許多主要生物製藥公司的所在地，這些公司正在投入大量資源來開發單株抗體和新藥。在亞太地區，由於醫療基礎設施的成長和慢性病的增加，對抗體治療的需求激增。此外，由於強大的研究機構和支持性政府政策的支持，個人化醫療和抗體開發取得了進步，亞太地區的抗體治療市場正在成長。歐盟 (EU) 國家擁有強大的製藥工業、廣泛的研究計畫和全面的智慧財產權框架，對抗體治療領域至關重要。此外，中東和非洲國家正在投資最先進的醫療設施和醫療保健創新。

FPNV定位矩陣

FPNV 定位矩陣對於評估供應商在抗體治療市場的定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對抗體治療市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外，該分析還提供了對該行業競爭性質的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對抗體治療市場當前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 各種癌症和感染疾病的發生率增加
      • 世界各地的藥物發現活動不斷增加
      • 政府努力促進獲得抗體治療和療法
    • 抑制因素
      • 產品召回的發生和抗體療法的嚴格核准指南
    • 機會
      • 抗體療法的臨床開發進展
      • 新型抗體療法和治療方法的核准正在進行中
    • 任務
      • 各種治療方法的療效不足和副作用
  • 市場區隔分析
    • 形式：由於臨床使用獲得了許多監管部門的核准，單株抗體的使用越來越多。
    • 給藥途徑：抗體療法的靜脈注射使用正在增加
    • 來源：由於生物相容性，人類抗體的使用增加
    • 疾病領域：感染疾病抗體療法的使用迅速增加
    • 最終使用者：改進抗體療法在醫院的使用
  • 市場趨勢分析
    • 由政府資助以及與美洲世界知名製藥公司合作的治療性抗體的先進研究和開發
    • 慢性病和感染疾病負擔日益增加，亞太地區對抗體治療的需求不斷增加
    • 隨著生物技術公司在歐洲、中東和非洲地區擴張，臨床試驗正在進行中
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章 抗體治療藥物市場格局

  • 抗體片段
  • 雙特異性抗體
  • 單株抗體
  • 多株抗體

第7章 抗體治療藥物市場：依給藥途徑分類

  • 靜脈
  • 皮下的

第8章抗體治療市場：依來源分類

  • 嵌合體
  • 人類
  • 人性化

第9章依疾病領域分類的抗體治療藥物市場

  • 自體免疫與發炎疾病
  • 血液學
  • 免疫學
  • 神經病學
  • 腫瘤學
  • 骨學

第10章抗體治療市場：依最終用戶分類

  • 醫院
  • 長期照護設施

第11章美洲抗體治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區抗體治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲抗體治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • SystImmune 和百時美施貴寶宣布就 BL-B01D1 的開發和商業化達成全球戰略合作夥伴協議
    • 艾伯維 (AbbVie) 和 Big Hat Biosciences 宣布開展研究合作，利用人工智慧和機器學習發現下一代治療抗體
    • 艾伯維（AbbVie）透過收購 Immunogen 擴大固態腫瘤產品組合，包括領先的癌症藥物 ELAHERE（mirvetuximab soravitansin-Zinx）
    • MBrace Therapeutics 在 B 系列資金籌措中籌集了 8,500 萬美元，以推進創新抗體藥物複合體候選物的腫瘤學管道
    • Saripro 與 Icosagen 合作開發單株抗體療法
    • AbCellera 和 Incyte 合作開發腫瘤治療抗體
    • 日本取得 BioArctic 帕金森氏症抗體專利
    • 美國FDA核准TALVEY，這是首個雙特異性療法，用於治療嚴重治療的多發性骨髓瘤患者
    • Crossbow Therapeutics 在 A 輪資金籌措中籌集了 8000 萬美元，開始開發抗體療法
    • Crossbow Therapeutics 在 A 輪資金籌措中籌集了 8000 萬美元，開始開發抗體療法
    • Pyxis Oncology 收購抗體治療公司 Apexigen
    • 默克斥資 108 億美元收購單株抗體
    • Genmab 和 AlgenX 合作推進免疫學和腫瘤學領域的抗體療法

第15章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-A42893A596E8

[197 Pages Report] The Antibody Therapeutics Market size was estimated at USD 248.79 billion in 2023 and expected to reach USD 285.77 billion in 2024, at a CAGR 14.89% to reach USD 657.50 billion by 2030.

Antibody therapeutics are a class of medical treatments that employ antibodies to mimic or enhance the immune system's ability to fight diseases. The precision of antibody therapeutics allows for tailored treatments that provide high specificity and lower toxicity profiles than conventional drugs, making them effective in treating various conditions, including cancers, autoimmune diseases, and infectious diseases. The increasing incidences of chronic diseases and increased healthcare expenditure globally have increased the adoption of antibody therapeutics. However, high costs associated with development and lengthy and complex regulatory approvals limit the penetration of antibody therapeutics. Nevertheless, advancements in medical technology are leading to more productive antibody production. In addition, the emergence of next-generation antibodies and supportive government initiatives for cancer care and treatments are expected to offer potential opportunities for the antibody therapeutics market.

KEY MARKET STATISTICS
Base Year [2023] USD 248.79 billion
Estimated Year [2024] USD 285.77 billion
Forecast Year [2030] USD 657.50 billion
CAGR (%) 14.89%

Regional Insights

In the Americas, antibody therapeutics market exhibit robust growth supported by a well-established R&D ecosystem, extensive patent portfolio, and high healthcare expenditure. Furthermore, the Americas includes numerous biopharmaceutical giants, which dedicate substantial resources to developing monoclonal antibodies and novel drug discovery. The Asia-Pacific region experienced a surge in the need for antibody therapeutics due to a growing healthcare infrastructure and increased incidences of chronic disease. Moreover, the Asia-Pacific region is witnessing growth in the antibody therapeutics market owing to the advances in personalized medicine and antibody development, supported by its strong research institutions and supportive government policies. Given their strong pharmaceutical industry, extensive research initiatives, and comprehensive intellectual property rights framework, European Union countries are pivotal in the antibody therapeutics landscape. In addition, countries in the Middle East and Africa are investing in state-of-the-art medical facilities and healthcare innovation.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Antibody Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Rising incidences of various cancers and infectious diseases
      • Increasing number of drug discovery activities worldwide
      • Government initiatives to promote access to antibody treatments and therapies
    • Market Restraints
      • Incidences of product recalls of antibody therapeutics coupled with strict approval guidelines
    • Market Opportunities
      • Advancements in the clinical development of antibody therapeutics
      • Ongoing approvals for novel antibody therapies and treatments
    • Market Challenges
      • Insufficient efficacy and adverse effects associated with various treatments
  • Market Segmentation Analysis
    • Format: Significant utilization of monoclonal antibodies due to numerous approvals by regulatory agencies for clinical use
    • Route of Administration: Growing usage of intravenous administration of antibody therapeutics
    • Source: Increasing use of human antibodies due to its biocompatible nature
    • Disease Areas: Proliferating use of antibody therapeutics for infectious diseases
    • End User: Evolving usage of antibody therapeutics in hospitals
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Antibody Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Antibody Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1

SystImmune entered into a pivotal license and collaboration agreement with Bristol Myers Squibb that focuses on the co-development and commercialization of the innovative BL-B01D1, an EGFRxHER3 bispecific antibody-drug conjugate (ADC) that is promising as a first-in-class therapy. Currently undergoing a Phase 1 clinical trial targeting non-small cell lung cancer (NSCLC), BL-B01D1 has already exhibited significant anti-tumor activity and a well-managed safety profile across various solid tumors. [Published On: 2023-12-11]

AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies

AbbVie Inc. partnered with BigHat Biosciences to drive the creation of cutting-edge therapeutic antibodies for oncology and neuroscience. This collaboration aims to streamline the discovery and optimization of superior antibodies for several key therapeutic targets. This initiative reflects the company's dedication to integrating AI and ML advancements into the drug development workflow to expedite the delivery of effective treatments. [Published On: 2023-12-05]

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

AbbVie announced the acquisition of ImmunoGen, a significant development that includes control of rights of ELAHERE (mirvetuximab soravtansine-gynx), ImmunoGen's premier cancer therapy. This acquisition is a testament to AbbVie's commitment to expanding its solid tumor treatment capabilities, positioning it to better address the complexities of cancer care. [Published On: 2023-11-30]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Antibody Therapeutics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AbCellera Biologics Inc., Adaptimmune Therapeutics PLC, ADC Therapeutics SA, Aenova Holding GmbH, Almac Group Limited, Amgen Inc., Antikor Biopharma, Argenx SE, Astellas Pharma Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biogen Inc., BioNTech SE, Bristol-Myers Squibb Company, Confo Therapeutics, DH Life Sciences, LLC, DotBio Pte. Ltd., Eli Lilly and Company, Emergent BioSolutions Inc., Evonik Industries AG, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc.,, Genmab A/S, GlaxoSmithKline PLC, Grifols, S.A., Incyte Corporation, iTeos Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Merus N.V., MoonLake Immunotherapeutics AG, MorphoSys AG, Novartis AG, Novo Nordisk A/S, Numab Therapeutics AG, Pfizer Inc., PharmAbcine Inc., Pyxis Oncology, Inc., Regeneron Pharmaceuticals, Inc., SAB Biotherapeutics, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., TRIO Pharmaceuticals Inc., UCB S.A., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Format
    • Antibody Fragment
    • Bispecific Antibody
    • Monoclonal Antibody
    • Polyclonal Antibody
  • Route of Administration
    • Intravenous
    • Subcutaneous
  • Source
    • Chimeric
    • Human
    • Humanized
  • Disease Areas
    • Autoimmune & Inflammatory Diseases
    • Hematology
    • Immunology
    • Neurology
    • Oncology
    • Osteology
  • End User
    • Hospitals
    • Long-term Care Facilities
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of various cancers and infectious diseases
      • 5.1.1.2. Increasing number of drug discovery activities worldwide
      • 5.1.1.3. Government initiatives to promote access to antibody treatments and therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Incidences of product recalls of antibody therapeutics coupled with strict approval guidelines
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the clinical development of antibody therapeutics
      • 5.1.3.2. Ongoing approvals for novel antibody therapies and treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Insufficient efficacy and adverse effects associated with various treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Format: Significant utilization of monoclonal antibodies due to numerous approvals by regulatory agencies for clinical use
    • 5.2.2. Route of Administration: Growing usage of intravenous administration of antibody therapeutics
    • 5.2.3. Source: Increasing use of human antibodies due to its biocompatible nature
    • 5.2.4. Disease Areas: Proliferating use of antibody therapeutics for infectious diseases
    • 5.2.5. End User: Evolving usage of antibody therapeutics in hospitals
  • 5.3. Market Trend Analysis
    • 5.3.1. Advanced R&D activities in antibody therapeutics backed by government funding and partnership activities by global established pharmaceutical companies in Americas
    • 5.3.2. Growing burden of chronic and infectious diseases creating need for antibody therapeutics in the Asia-Pacific
    • 5.3.3. Ongoing clinical trials coupled with expansion of biotech companies in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Antibody Therapeutics Market, by Format

  • 6.1. Introduction
  • 6.2. Antibody Fragment
  • 6.3. Bispecific Antibody
  • 6.4. Monoclonal Antibody
  • 6.5. Polyclonal Antibody

7. Antibody Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Subcutaneous

8. Antibody Therapeutics Market, by Source

  • 8.1. Introduction
  • 8.2. Chimeric
  • 8.3. Human
  • 8.4. Humanized

9. Antibody Therapeutics Market, by Disease Areas

  • 9.1. Introduction
  • 9.2. Autoimmune & Inflammatory Diseases
  • 9.3. Hematology
  • 9.4. Immunology
  • 9.5. Neurology
  • 9.6. Oncology
  • 9.7. Osteology

10. Antibody Therapeutics Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals
  • 10.3. Long-term Care Facilities

11. Americas Antibody Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antibody Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antibody Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
    • 14.3.2. AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
    • 14.3.3. AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
    • 14.3.4. MBrace Therapeutics Raises USD 85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates
    • 14.3.5. Salipro Partners with Icosagen to Develop Monoclonal Antibody Therapies
    • 14.3.6. AbCellera, Incyte Partner on Therapeutic Antibodies in Oncology
    • 14.3.7. Japan Grants Patent for Bioarctic's Parkinson's Disease Antibody
    • 14.3.8. U.S. FDA Approves TALVEY, a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
    • 14.3.9. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
    • 14.3.10. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
    • 14.3.11. Pyxis Oncology to acquire Antibody Therapeutics Company Apexigen
    • 14.3.12. Merck to Develop mAb Through USD 10.8 Billion Acquisition
    • 14.3.13. Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIBODY THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OSTEOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OSTEOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 294. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 297. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 298. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 299. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 300. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 301. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 302. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 303. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 304. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 307. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 308. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 309. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 310. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 311. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 312. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 313. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 314. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 315. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 316. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 317. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 318. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 319. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 320. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 321. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 322. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 323. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 324. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 325. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 326. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 327. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 328. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 330. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 332. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 334. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2023 (USD MILLION)
  • TABLE 336. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024-2030 (USD MILLION)
  • TABLE 337. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 338. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 339. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2023 (USD MILLION)
  • TABLE 340. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024-2030 (USD MILLION)
  • TABLE 341. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 342. NIGERIA ANTIBODY TH